


FORM PTO-1595
(Rev. 6-93)
OMB No. 0651-0011 (exp. 4/94)



U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

David Lauffer,
Brian Ledford,
Michael Mullican,

01/03/02

2. Name and address of receiving party(ies)

Name: Vertex Pharmaceuticals Incorporated

Internal Address: Patent Department

Street Address: 130 Waverly Street, Cambridge, MA 02139-4242

j1036 U.S. PTO
10/039896
01/03/02

Additional name(s) of conveying party(ies) attached? ☐ Yes ☐ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other _____

Additional name(s) & address(es) attached? ☐ Yes ☐ No

Execution Date: July 6, 2000

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is _____

A. Patent Application No(s):

PCT/US00/18564

60/142,568

B. Patent No(s):

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence
Concerning document should be mailed:

Name: Nandakumar Govindaswamy, Ltd. Recognition
Address: VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, MA 02138-4242

6. Total number of applications and patents involved: [2]

7. Total fee (37 CFR 3.41)

\$40.00

- ☐ Enclosed
☒ The Commissioner is authorized to charge Deposit Account
No: 50-0725, Reference No. VPI/98-21 US.

DO NOT USE THIS SPACE

9. Statement and signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Andrew S. Marks, Registration No. 33,259

1/3/02

Name of Person Signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: [7]

Mail documents to be recorded with required cover sheet information to:

BOX ASSIGNMENT
P.O. Box 2327
Arlington, VA 22202

TRADOCS:1316516.1(S7TW01!.DOC)

01/29/2002 GTOW11 00000162 500725 10039896

01 FC:581 40.00 CH

PATENT
REEL: 012509 FRAME: 0660

PCT
ASSIGNMENT

I/We,

- (1) David Lauffer,
- (2) Brian Ledford,
- (3) Michael Mullican,

residing, respectively, at

- (1) 254 Taylor Road
Stow, Massachusetts 01775 U.S.A.,
- (2) 36 School Street
Hopkinton, Massachusetts 01748 U.S.A.,
- (3) 110 Parker Road
Needham, Massachusetts 02194 U.S.A.,

for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of the COMMONWEALTH OF MASSACHUSETTS and having an office and a place of business at 130 WAVERLY STREET, CAMBRIDGE, MASSACHUSETTS 02139-4242, its successors and assigns: (1) the entire right, title and interest in all countries throughout the world in and to any and all my/our inventions and discoveries disclosed in my/our International Patent Application, filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US), entitled: "N-SUBSTITUTED GLYCINE DERIVATIVES" and designating Albania (AL), Algeria (DZ), Antigua & Barbuda (AG), Armenia (AM),

Australia (AU), Austria (AT), Azerbaijan (AZ), Barbados (BB), Belarus (BY), Belgium (BE), Benin (BJ), Bosnia and Herzegovina (BA), Brazil (BR), Bulgaria (BG), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), China (CN), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czech Republic (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Dominica (DM), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Greece (GR), Grenada (GD), Guinea (GN), Guinea Bissau (GW), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Ireland (IE), Israel (IL), Italy (IT), Japan (JP), Kazakhstan (KZ), Kenya (KE), Kyrgyzstan (KG), Latvia (LV), Lesotho (LS), Liberia (LR), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), former Yugoslav Republic of Macedonia (MK), Malawi (MW), Mali (ML), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Morocco (MA), Mozambique (MZ), Netherlands (NL), New Zealand (NZ), Niger (NE), Norway (NO), Poland (PL), Portugal (PT), Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Saint Lucia (LC), Senegal (SN), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Tajikistan (TJ), Tanzania (TZ), Togo (TG), Trinidad and Tobago (TT), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Yugoslavia (YU), and Zimbabwe (ZW), [subsequently

identified as International Patent Application, filed PCT/US00/18564 06 July 2000, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of VERTEX PHARMACEUTICALS INCORPORATED, its designee, or in my/our names at VERTEX PHARMACEUTICALS INCORPORATED, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue on the aforesaid inventions, discoveries and applications in any country of the world and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the following priority application(s):

<u>60/142,568</u>	<u>United States</u>	<u>July 6, 1999</u>
application no.	country	filing date

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

* I/We hereby authorize VERTEX PHARMACEUTICALS INCORPORATED and its representatives to insert in this instrument the International Patent Application number and the filing date of said application when VERTEX PHARMACEUTICALS INCORPORATED is officially notified thereof.

I/We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in any country throughout the world to VERTEX PHARMACEUTICALS INCORPORATED as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.

I/We agree, at any time, upon the request of VERTEX PHARMACEUTICALS INCORPORATED to execute and to deliver to VERTEX PHARMACEUTICALS INCORPORATED any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

I/We further agree, at any time, upon request of VERTEX PHARMACEUTICALS INCORPORATED to execute and to deliver to VERTEX PHARMACEUTICALS INCORPORATED such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect any and all rights of VERTEX PHARMACEUTICALS INCORPORATED under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNORS:

David Laufer (1)
David Laufer

Brian Ledford (2)
Brian Ledford

Michael Mullican (3)
Michael Mullican

On this 2nd day of July, 2000,
David Laufer (1) personally appeared before me, a Notary
Public in and for the Commonwealth of Massachusetts, and
executed the foregoing Assignment and duly acknowledged
to me that such Assignment was executed for the uses and
purposes therein expressed.

Phyllis A. Tobey
Notary Public

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8, 2003

On this 2nd day of July, 2000,
Brian Ledford (2) personally appeared before me, a Notary
Public in and for the Commonwealth of Massachusetts, and
executed the foregoing Assignment and duly acknowledged
to me that such Assignment was executed for the uses and
purposes therein expressed.

Phyllis A. Tobey
Notary Public

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8, 2003


On this 2nd day of July, 2000,
Michael Mullican (3) personally appeared before me, a
Notary Public in and for the Commonwealth of
Massachusetts, and executed the foregoing Assignment and
duly acknowledged to me that such Assignment was executed
for the uses and purposes therein expressed.


Notary Public

ACKNOWLEDGEMENT OF ASSIGNEE:

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8, 2003

VERTEX PHARMACEUTICALS INCORPORATED

By: 
Andrew S. Marks
Chief Patent Counsel

On this 2nd day of July, 2000,
Andrew S. Marks personally appeared before me, a Notary
Public in and for the Commonwealth of Massachusetts, and
duly acknowledged the executed Assignment on behalf of
the Assignee.


Notary Public

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8, 2003